Longeveron (LGVN) Revenue Growth (1y) (2021 - 2026)
Longeveron (LGVN) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Revenue Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
37.90% |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
64.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
7.82% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
4.46% |
| Date | Value |
|---|
| Mar 31, 2026 |
4.46% |
| Dec 31, 2025 |
-39.47% |
| Sep 30, 2025 |
-82.28% |
| Jun 30, 2025 |
-32.48% |
| Mar 31, 2025 |
-30.47% |
| Dec 31, 2024 |
857.14% |
| Sep 30, 2024 |
415.33% |
| Jun 30, 2024 |
115.67% |
| Mar 31, 2024 |
96.42% |
| Dec 31, 2023 |
-47.93% |
| Sep 30, 2023 |
50.00% |
| Jun 30, 2023 |
-53.43% |
| Mar 31, 2023 |
-24.59% |
| Dec 31, 2022 |
-42.11% |
| Sep 30, 2022 |
-56.90% |
| Jun 30, 2022 |
-4.70% |
| Mar 31, 2022 |
-1.60% |
| Dec 31, 2021 |
-96.08% |
| Sep 30, 2021 |
-87.56% |
| Jun 30, 2021 |
63.00% |
